Regulatory Approvals

Recon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88B

By

Regulatory Approvals — Recon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88B  RAPS

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. August 31, 2026.

By

Related Post

Regulatory Approvals

FDA Approves Mimrylo for Polycythemia Vera, Offering a New Treatment Approach

Regulatory Approvals

F.D.A. Approves New Covid Vaccines, and They Should Be Available Soon

Regulatory Approvals

FDA Approves Rusfertide for Polycythemia Vera

Financial News For All

Labor

545 employees of VCU Health contractor face layoffs

Labor

Washington state workers stage walkout over proposed agency cuts

Labor

Some Pierce County Amazon workers face layoffs. Here’s what we know

Regulatory Approvals

F.D.A. Approves New Covid Vaccines, and They Should Be Available Soon